

Olanzapine/Samidorphan : Adis Evaluation

Clinical Considerations

- **New opioid antagonist co-formulated with olanzapine**
- **Maintains olanzapine efficacy while mitigating olanzapine-associated weight gain**
- **Generally well tolerated**

Plain Language Summary

Background and rationale

- Weight gain and significant changes in metabolism are commonly caused by second-generation/atypical antipsychotics, including olanzapine
- Olanzapine is one of the most effective antipsychotics, but is also associated with a high risk of weight gain especially at higher doses and with prolonged treatment
- Weight gain can impact adherence, and thus treatment outcomes associated with antipsychotics
- The combination of olanzapine with the new opioid antagonist samidorphan (olanzapine/samidorphan; LYBALVI®) is indicated for the treatment of adults with schizophrenia or bipolar I disorder, and offers the efficacy of olanzapine while mitigating olanzapine-associated weight gain

Clinical findings

- Compared with olanzapine, olanzapine/samidorphan had similar antipsychotic efficacy and led to significantly less weight gain
- The benefits of olanzapine/samidorphan were durable with longer-term therapy

Conclusion

Olanzapine/samidorphan is a useful option for the treatment of schizophrenia and bipolar I disorder

This plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.